Relapsed and refractory CD19 positive B-cell acute lymphoblastic leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) are the focus of studies in hematological cancers…In addition, ISIKOK-19 cells demonstrated a significant high level of cytotoxicity specifically against a CD19+ B-lymphocyte cancer model, RAJI cells, in NOD/SCID mice. This is the first report of preclinical assessment of efficacy and safety analysis of CAR-T cells (ISIKOK-19) targeting CD19-expressing B cells in relapsed/refractory ALL and NHL patients in Turkey.